PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28746193-1 2017 High-dose atorvastatin pretreatment was proved reducing the risk of contrast-induced acute kidney injury (CI-AKI), especially in patients with high C-reactive protein (CRP) levels. Atorvastatin 10-22 C-reactive protein Homo sapiens 148-166 28746193-1 2017 High-dose atorvastatin pretreatment was proved reducing the risk of contrast-induced acute kidney injury (CI-AKI), especially in patients with high C-reactive protein (CRP) levels. Atorvastatin 10-22 C-reactive protein Homo sapiens 168-171 27749321-8 2017 The increments of serum omentin-1 levels with atorvastatin administration inversely correlated with changes in LDL cholesterol (r=-0.145, P=0.041), interleukin-6 (r=-0.162, P=0.023), and high-sensitivity C-reactive protein (r=-0.185, P=0.009) in patients with CAD. Atorvastatin 46-58 C-reactive protein Homo sapiens 204-222 28577105-5 2017 Atorvastatin therapy significantly reduced the levels of VEGF (by 11%), C-reactive protein (by 26%), total cholesterol (by 30%), LDL cholesterol (by 35%), and triglycerides (by 18%); the levels of endostatin, MCP-1, and HDL cholesterol remained unchanged. Atorvastatin 0-12 C-reactive protein Homo sapiens 72-90 26566148-0 2017 Effects of Atorvastatin on Serum High-Sensitive C-Reactive Protein and Total Cholesterol Levels in Asian Patients With Atrial Fibrillation. Atorvastatin 11-23 C-reactive protein Homo sapiens 48-66 27522390-6 2016 RESULTS: Clinical and experimental parts showed that groups with RIPC combined with atorvastatin pre-treatment showed a synergistic protective effect against I/R injury as evidenced by significant reduction (P<0.001) in the levels of TNF-alpha, cTnI (in patients) and IL-6, CK-MB and CRP (in rabbits) while the level of NO was significantly (P<0.001) increased compared with other groups. Atorvastatin 84-96 C-reactive protein Homo sapiens 277-290 26271127-1 2016 We conducted a meta-analysis of 13 randomized trials comparing the efficacy of rosuvastatin versus atorvastatin in reducing concentrations of C-reactive protein (CRP). Atorvastatin 99-111 C-reactive protein Homo sapiens 142-160 27084958-8 2016 Three-month atorvastatin 40 mg daily significantly lowered low-density lipoprotein cholesterol (baseline 3.55+-1.15 mmol/L, -53%) and CRP (baseline 5.0 (1.5-9.3) mg/L, -58%) with a concomitant decrease of carotid arterial wall inflammation (maximum target-to-background ratio from 1.90+-0.30 to 1.67+-0.27; p=0.009). Atorvastatin 12-24 C-reactive protein Homo sapiens 134-137 26271127-0 2016 Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia. Atorvastatin 41-53 C-reactive protein Homo sapiens 83-101 27725801-9 2016 The treatment with atorvastatin was associated with a decrease in C-reactive protein and interleukin-6 by 23.1 and 49.2%, respectively, compared with baseline values. Atorvastatin 19-31 C-reactive protein Homo sapiens 66-84 26271127-1 2016 We conducted a meta-analysis of 13 randomized trials comparing the efficacy of rosuvastatin versus atorvastatin in reducing concentrations of C-reactive protein (CRP). Atorvastatin 99-111 C-reactive protein Homo sapiens 162-165 27287781-13 2016 This study shows that atorvastatin and its metabolites are detectable in breast samples and may lower serum CRP among women without hyperlipidemia. Atorvastatin 22-34 C-reactive protein Homo sapiens 108-111 26333596-8 2016 The beneficial effects on AF and CRP were more marked in patients receiving atorvastatin compared to other statins. Atorvastatin 76-88 C-reactive protein Homo sapiens 33-36 27075863-1 2016 BACKGROUND: This randomized controlled trial aimed to evaluate the effects of seven-day preoperative treatment with two different dosages of atorvastatin on the incidence of postoperative atrial fibrillation (POAF) and release of inflammatory markers such as high-sensitive C-reactive protein (hsCRP) and interleukin-6 in patients undergoing elective first-time on-pump coronary artery bypass grafting (CABG). Atorvastatin 141-153 C-reactive protein Homo sapiens 274-292 27437268-8 2016 SJC, TJC, CRP and ESR also were significantly dropped in the atorvastatin group in comparison with placebo. Atorvastatin 61-73 C-reactive protein Homo sapiens 10-13 26747436-8 2016 The effect size on plasma CRP concentrations was significant with lipophilic (atorvastatin) but not hydrophilic (pravastatin and rosuvastatin) statins. Atorvastatin 78-90 C-reactive protein Homo sapiens 26-29 23948514-0 2013 Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm. Atorvastatin 86-98 C-reactive protein Homo sapiens 14-32 26697531-9 2016 However, the serum lipids and CRP concentrations were significantly lower after one month of atorvastatin therapy in both groups of patients - with decreased and increased MPO gene expression. Atorvastatin 93-105 C-reactive protein Homo sapiens 30-33 26311995-6 2015 CRP levels significantly decreased from beginning to the end of 4 weeks in both atorvastatin and rosuvastatin groups (from 35.48 to 23.07 mg/l and from 35.88 to 19.91 mg/l respectively, both P < 0.001). Atorvastatin 80-92 C-reactive protein Homo sapiens 0-3 26311995-9 2015 CONCLUSION: Both atorvastatin (40 mg) and rosuvastatin (20 mg) are effective in decreasing CRP and LDL cholesterol levels even in a short duration of 4 weeks. Atorvastatin 17-29 C-reactive protein Homo sapiens 91-94 25369444-9 2014 The median decrease in the high-sensitivity C-reactive protein and interleukin-6 levels was significantly greater in the atorvastatin reload group (P<0.001). Atorvastatin 121-133 C-reactive protein Homo sapiens 44-62 25538368-0 2014 Effects of high versus low-dose atorvastatin on high sensitive C-reactive protein in acute coronary syndrome. Atorvastatin 32-44 C-reactive protein Homo sapiens 63-81 25538368-2 2014 The previous findings which suggest the reduction in C-reactive protein (CRP) levels by statin encouraged us to conduct the present study in which we tested the effects of atorvastatin, on levels of hs-CRP in a prospective randomised clinical trial study on patients with acute coronary syndrome. Atorvastatin 172-184 C-reactive protein Homo sapiens 202-205 25538368-8 2014 In this study atorvastatin in high doses decreased hs-CRP levels about 40% and in low doses it only caused decrease of 13.3%, and significant correlation was observed between two groups (Paired Sample T-test) (P = 0.001). Atorvastatin 14-26 C-reactive protein Homo sapiens 54-57 25538368-11 2014 CONCLUSION: The present study confirms the novel observation that atorvastatin therapy results in a significant reduction in hs-CRP levels. Atorvastatin 66-78 C-reactive protein Homo sapiens 128-131 25899452-2 2015 METHODS: CRP levels were measured at baseline and 1 year after randomisation to atorvastatin in 2,322 patients with type 2 diabetes (40-75 years, 69% males) in a secondary analysis of the Collaborative Atorvastatin Diabetes Study, a randomised placebo-controlled trial. Atorvastatin 80-92 C-reactive protein Homo sapiens 9-12 25899452-4 2015 RESULTS: After 1 year, the atorvastatin arm showed a net CRP lowering of 32% (95% CI -40%, -22%) compared with placebo. Atorvastatin 27-39 C-reactive protein Homo sapiens 57-60 26229958-0 2015 Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels. Atorvastatin 0-12 C-reactive protein Homo sapiens 78-96 26229958-1 2015 We investigated whether serum hs-CRP levels predict the efficacy of atrial fibrillation (AF) treated with atorvastatin. Atorvastatin 106-118 C-reactive protein Homo sapiens 33-36 26229958-4 2015 Our meta-analysis identified seven cohort studies (2006~2013), providing information on the change in serum hs-CRP levels in AF patients receiving atorvastatin therapy. Atorvastatin 147-159 C-reactive protein Homo sapiens 111-114 26229958-5 2015 After atorvastatin treatment, hs-CRP level in AF patients decreased significantly (SMD = 1.02, 95% CI: 0.58-1.47, P < 0.001). Atorvastatin 6-18 C-reactive protein Homo sapiens 33-36 26229958-6 2015 Subgroup analysis by country and hs-CRP detection methods suggested a negative relationship between atorvastatin treatment and hs-CRP levels among Chinese AF patients (SMD = 1.34, 95% CI: 1.00-1.69, P < 0.001) and by using ELISA method (SMD = 1.11, 95% CI: 0.51-1.71, P < 0.001), but not among Turkish population and using INA method (all P > 0.05). Atorvastatin 100-112 C-reactive protein Homo sapiens 36-39 26229958-6 2015 Subgroup analysis by country and hs-CRP detection methods suggested a negative relationship between atorvastatin treatment and hs-CRP levels among Chinese AF patients (SMD = 1.34, 95% CI: 1.00-1.69, P < 0.001) and by using ELISA method (SMD = 1.11, 95% CI: 0.51-1.71, P < 0.001), but not among Turkish population and using INA method (all P > 0.05). Atorvastatin 100-112 C-reactive protein Homo sapiens 130-133 26229958-8 2015 hs-CRP was clearly lowered in AF patients treated with atorvastatin, which may be helpful in the choice of statin agents for AF treatment. Atorvastatin 55-67 C-reactive protein Homo sapiens 3-6 24198051-6 2014 On the other hand, serum oxidized LDL and high-sensitivity C-reactive protein were lower in the atorvastatin treatment period than in the ezetimibe treatment period (109 +- 38 vs 146 +- 67 U/L, p = 0.002; 1.02 +- 1.46 vs 1.47 +- 1.77 microg/mL, p = 0.003). Atorvastatin 96-108 C-reactive protein Homo sapiens 59-77 23436914-0 2014 Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Atorvastatin 43-55 C-reactive protein Homo sapiens 134-152 24778661-2 2014 This study designed to evaluate the effects of atorvastatin on serum highly sensitive C-reactive protein (hs-CRP) and pulmonary function in sulfur mustard exposed patients with COPD. Atorvastatin 47-59 C-reactive protein Homo sapiens 86-104 23948514-7 2013 After 6 months of atorvastatin therapy, the median LDL-C and CRP were reduced by 38.7% and 25.8%, respectively. Atorvastatin 18-30 C-reactive protein Homo sapiens 61-64 23791132-7 2013 In VTE patients atorvastatin decreased IL-6 (p=0.0003), IL-8 (p=0.003) and P-selectin (p<0.0001), but increased IL-10 (p=0.001), with no association with C-reactive protein or cholesterol-lowering effects. Atorvastatin 16-28 C-reactive protein Homo sapiens 157-175 23324897-5 2013 Only atorvastatin showed a statistically significant increase in NO (15.19%, P<0.05), eNOS (20.58%, P<0.01), IIEF-5 score (53.1%, P<0.001) and Rigiscan rigidity parameters (P<0.01), in addition to a statistically significant decrease in CRP (57.9%, P<0.01). Atorvastatin 5-17 C-reactive protein Homo sapiens 249-252 22528165-2 2012 In this trial, we evaluated the perioperative effects on C-reactive protein (CRP) that resulted from starting atorvastatin within seven days of noncardiac surgery. Atorvastatin 110-122 C-reactive protein Homo sapiens 57-75 23507424-7 2013 Atorvastatin alone or combined with ezetimibe reduced both LDL-cholesterol and CRP (P<0.002 vs. baseline; Wilcoxon); ezetimibe did not modify CRP. Atorvastatin 0-12 C-reactive protein Homo sapiens 59-82 23507424-7 2013 Atorvastatin alone or combined with ezetimibe reduced both LDL-cholesterol and CRP (P<0.002 vs. baseline; Wilcoxon); ezetimibe did not modify CRP. Atorvastatin 0-12 C-reactive protein Homo sapiens 79-82 23218801-0 2013 Effects of atorvastatin on human C-reactive protein metabolism. Atorvastatin 11-23 C-reactive protein Homo sapiens 33-51 23218801-2 2013 Our goal was to define the mechanisms by which CRP was reduced by maximal dose atorvastatin. Atorvastatin 79-91 C-reactive protein Homo sapiens 47-50 23218801-10 2013 CONCLUSION: Our data indicate that maximal doses of atorvastatin lower plasma CRP levels by substantially decreasing the median CRP plasma residence time from 2.94 days to 2.0 days, with no significant effect on the median CRP production rate. Atorvastatin 52-64 C-reactive protein Homo sapiens 78-81 23218801-10 2013 CONCLUSION: Our data indicate that maximal doses of atorvastatin lower plasma CRP levels by substantially decreasing the median CRP plasma residence time from 2.94 days to 2.0 days, with no significant effect on the median CRP production rate. Atorvastatin 52-64 C-reactive protein Homo sapiens 128-131 23218801-10 2013 CONCLUSION: Our data indicate that maximal doses of atorvastatin lower plasma CRP levels by substantially decreasing the median CRP plasma residence time from 2.94 days to 2.0 days, with no significant effect on the median CRP production rate. Atorvastatin 52-64 C-reactive protein Homo sapiens 128-131 22879630-12 2012 CONCLUSIONS: Twelve weeks of atorvastatin led to a significant reduction in oxidative stress as determined by MDA concentrations among patients with polycystic ovary syndrome that was independently predicted by changes in testosterone, 25OHD, and high-sensitivity C-reactive protein. Atorvastatin 29-41 C-reactive protein Homo sapiens 264-282 22528165-2 2012 In this trial, we evaluated the perioperative effects on C-reactive protein (CRP) that resulted from starting atorvastatin within seven days of noncardiac surgery. Atorvastatin 110-122 C-reactive protein Homo sapiens 77-80 22448235-11 2012 CONCLUSIONS/SIGNIFICANCE: Atorvastatin treatment may be effective in slowing the decline of beta cell function in a patient subgroup defined by above median levels of CRP and other inflammation associated immune mediators. Atorvastatin 26-38 C-reactive protein Homo sapiens 167-170 21610204-0 2012 Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Atorvastatin 90-102 C-reactive protein Homo sapiens 57-75 21610204-6 2012 However, after propensity matching, atorvastatin lowered LDL-C and high-sensitivity C-reactive protein (hs-CRP) to a similar degree in both groups, with no differences in safety profile. Atorvastatin 36-48 C-reactive protein Homo sapiens 84-102 21920481-8 2012 Mean CRP levels decreased in the atorvastatin group (mean change -0.75 +- 3, P = .02) and increased in the placebo group (mean change 2.1 +- 19.9, P = .48). Atorvastatin 33-45 C-reactive protein Homo sapiens 5-8 21798891-0 2012 Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Atorvastatin 90-102 C-reactive protein Homo sapiens 14-32 21584495-0 2011 Atorvastatin reduces lipopolysaccharide-induced expression of C-reactive protein in human lung epithelial cells. Atorvastatin 0-12 C-reactive protein Homo sapiens 62-80 23654149-3 2012 Additional use of atorvastatin to a conventional therapy leads to significant reduction of C-reactive protein and fibrinogen and improves effect of long-term sinus rhythm maintenance. Atorvastatin 18-30 C-reactive protein Homo sapiens 91-109 22321227-1 2011 OBJECTIVE: To observe the association between preprocedural high sensitivity C-reactive protein (hs-CRP) level and incidence of contrast induced acute kidney injury (CI-AKI) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) and the impact of atorvastatin pretreatment on CI-AKI. Atorvastatin 286-298 C-reactive protein Homo sapiens 77-95 21774822-11 2011 CONCLUSIONS: In SLE patients 40 mg of atorvastatin daily for 1 year led to a decrease in serum lipids and CRP levels. Atorvastatin 38-50 C-reactive protein Homo sapiens 106-109 21584495-3 2011 In this study, we determined whether atorvastatin modulates the lipopolysaccharide (LPS)-induced expression of CRP in A549 cells. Atorvastatin 37-49 C-reactive protein Homo sapiens 111-114 21584495-8 2011 The present study revealed that A549 cells are capable of LPS-induced CRP expression, and that atorvastatin down-regulates the LPS-induced expression of CRP in cultured A549 cells. Atorvastatin 95-107 C-reactive protein Homo sapiens 153-156 22088250-0 2011 [The effects of atorvastatin on C-reactive protein induced Toll-like receptor 4 expression on CD14+ monocyte]. Atorvastatin 16-28 C-reactive protein Homo sapiens 32-50 22088250-1 2011 OBJECTIVE: To investigate the effects of atorvastatin on C-reactive protein (CRP) induced Toll-Like receptor 4 (TLR4)expression on CD14+ monocyte, and the production of proinflammatory cytokines tumor necrosis factor alpha (TNFalpha), interleukin-6 (IL-6), matrix metalloproteinases-9 (MMP-9), and to study the anti-inflammatory mechanisms of statins. Atorvastatin 41-53 C-reactive protein Homo sapiens 57-75 22088250-1 2011 OBJECTIVE: To investigate the effects of atorvastatin on C-reactive protein (CRP) induced Toll-Like receptor 4 (TLR4)expression on CD14+ monocyte, and the production of proinflammatory cytokines tumor necrosis factor alpha (TNFalpha), interleukin-6 (IL-6), matrix metalloproteinases-9 (MMP-9), and to study the anti-inflammatory mechanisms of statins. Atorvastatin 41-53 C-reactive protein Homo sapiens 77-80 22088250-7 2011 (2) TLR4 protein expression on 50 microg/ml CRP stimulated cells also increased in a time-dependent manner (29.80 +/- 2.70)%, (47.44 +/- 4.41)%, (81.71 +/- 2.92)% and (50.57 +/- 3.34)% after 6 h, 12 h, 24 h, 48 h. (3) When monocytes were incubated with CRP 50 microg/ml and atorvastatin (1.0, 2.5, 5.0, 7.5, 10.0 micromol/L), protein expression [(68.17 +/- 1.71)%, (52.43 +/- 1.38)%, (27.72 +/- 4.55)%, (17.46 +/- 3.20)%, (9.99 +/- 2.81)%] and mRNA expression (82.72%, 67.34%, 48.16%, 30.88%, 13.85%) of TLR4 as well as mRNA expression of MD2 (81.78%, 71.04%, 47.85%, 27.06%, 18.30%) were reduced in a dose-dependent manner. Atorvastatin 274-286 C-reactive protein Homo sapiens 44-47 22088250-9 2011 When monocyte incubated with CRP 50 microg/ml and atorvastatin 10.0 micromol/L, the level of TNFalpha, IL-6, MMP-9 decreased to (25.8 +/- 2.5) microg/ml, (128.2 +/- 14.7) pg/ml, (65.2 +/- 12.3) ng/ml, respectively. Atorvastatin 50-62 C-reactive protein Homo sapiens 29-32 22088250-11 2011 Atorvastatin can inhibit the signal transduction of TLR4 and reduce proinflammatory cytokines release induced by CRP on CD14 monocyte, and this might be one of the anti-inflammatory mechanisms of atorvastatin. Atorvastatin 0-12 C-reactive protein Homo sapiens 113-116 22088250-11 2011 Atorvastatin can inhibit the signal transduction of TLR4 and reduce proinflammatory cytokines release induced by CRP on CD14 monocyte, and this might be one of the anti-inflammatory mechanisms of atorvastatin. Atorvastatin 196-208 C-reactive protein Homo sapiens 113-116 21713097-17 2011 There was reduction in CRP after treatment with atorvastatin, suggesting improvement in endothelial function. Atorvastatin 48-60 C-reactive protein Homo sapiens 23-26 21943003-7 2011 Therapy with 10 mg/day atorvastatin was more effective in carriers of polymorphic marker Trp719Arg of KIF6 gene by action on dynamics of changes of high sensitivity C-reactive protein and dispersion of high density lipoprotein response. Atorvastatin 23-35 C-reactive protein Homo sapiens 165-183 21412424-11 2011 Median levels of total cholesterol and C-reactive protein decreased in the atorvastatin group only (p<0.001 and p = 0.04). Atorvastatin 75-87 C-reactive protein Homo sapiens 39-57 21298210-0 2011 ASCOT analysis with atorvastatin shows limits of CRP as indicator of cardiovascular risk. Atorvastatin 20-32 C-reactive protein Homo sapiens 49-52 21321461-6 2011 Atorvastatin significantly reduced the incidence of postoperative AF and postoperative peak CRP level versus placebo (18% versus 41%, P = 0.017; 129.3 +- 24.3 mg/L versus 149.3 +- 32.5 mg/L, P < 0.0001). Atorvastatin 0-12 C-reactive protein Homo sapiens 92-95 21045713-1 2011 OBJECTIVES: Short-term high-dose atorvastatin administered before percutaneous coronary intervention (PCI) reduces the rate of periprocedural myocardial infarction (pMI) in high-risk patients, such as those with acute coronary syndromes and those with elevated high-sensitivity C-reactive protein. Atorvastatin 33-45 C-reactive protein Homo sapiens 278-296 21169815-7 2011 Markers of the two groups were elevated after PCI; however, the higher values of creatine kinase-MB, cardiac troponin I, and high-sensitivity C-reactive protein in the atorvastatin treatment group were significantly lower than those in the placebo group (P<0.01). Atorvastatin 168-180 C-reactive protein Homo sapiens 142-160 21257003-2 2011 Our purpose was to compare the effects of maximum doses of rosuvastatin and atorvastatin on the plasma levels of the insulin, glycated albumin, adiponectin, and C-reactive protein compared to baseline in hyperlipidemic patients. Atorvastatin 76-88 C-reactive protein Homo sapiens 161-179 21257003-7 2011 Both atorvastatin and rosuvastatin caused significant (p <0.001) and similar median reductions in the C-reactive protein level of -40% and -26% compared to the baseline values. Atorvastatin 5-17 C-reactive protein Homo sapiens 105-123 21257003-9 2011 In conclusion, our data have indicated that the maximum dosage of atorvastatin or rosuvastatin therapy significantly lower C-reactive protein levels but also moderately increase insulin levels. Atorvastatin 66-78 C-reactive protein Homo sapiens 123-141 20494902-6 2010 High-sensitivity C-reactive protein fell by 40% in patients receiving atorvastatin but there was no change with amlodipine. Atorvastatin 70-82 C-reactive protein Homo sapiens 17-35 20091096-0 2010 Inhibition of C-reactive protein induced expression of matrix metalloproteinases by atorvastatin in THP-1 cells. Atorvastatin 84-96 C-reactive protein Homo sapiens 14-32 21273686-6 2010 All three biomarkers of inflammation significantly decreased after atorvastatin: CRP from 4.08 +- 3.72 to 2.97 +- 3.26 mug/ml (p < 0.05), IL-6 from 20.66 +- 20.05 to 13.36 +- 11.21 pg/ml (p < 0.05) and MCP-1 from 271.08 +- 85.72 to 213.24 +- 115.09 pg/ml (p < 0.05). Atorvastatin 67-79 C-reactive protein Homo sapiens 81-84 20805273-0 2010 Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes. Atorvastatin 21-33 C-reactive protein Homo sapiens 63-81 20805273-7 2010 CRP of individuals taking atorvastatin was significantly lower than when they were taking simvastatin (median 1.08 vs. 1.47 mg/l, P = 0.0002) and was less variable (median SD of logCRP 0.0036 vs. 0.178, P = 0.0001). Atorvastatin 26-38 C-reactive protein Homo sapiens 0-3 19201044-0 2010 C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Atorvastatin 178-190 C-reactive protein Homo sapiens 0-18 19201044-0 2010 C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Atorvastatin 178-190 C-reactive protein Homo sapiens 20-23 19201044-6 2010 Further, atorvastatin was used as a therapeutic modality for modulation of these genes in the presence of CRP. Atorvastatin 9-21 C-reactive protein Homo sapiens 106-109 19201044-9 2010 Effect of atorvastatin was also determined in the presence of CRP on the expression of these genes. Atorvastatin 10-22 C-reactive protein Homo sapiens 62-65 19201044-12 2010 Atorvastatin in a dose of 20 muM, was able to attenuate up-regulation of CRP-induced genes (p<0.01) and effects were both dose and time-dependent. Atorvastatin 0-12 C-reactive protein Homo sapiens 73-76 19217176-3 2010 We investigated the effect of atorvastatin, across its dose range, on high sensitivity (hs)CRP in subjects at high cardiovascular risk. Atorvastatin 30-42 C-reactive protein Homo sapiens 91-94 20545993-9 2010 RESULTS: The baseline characteristics of patients were similar among three groups; however, high-sensitive C-reactive protein (hs-CRP) levels were lower in atorvastatin group than placebo group. Atorvastatin 156-168 C-reactive protein Homo sapiens 107-125 20091096-4 2010 Effect of atorvastatin was determined in the presence of CRP on the expression of genes. Atorvastatin 10-22 C-reactive protein Homo sapiens 57-60 20091096-8 2010 Atorvastatin was able to significantly attenuate CRP-induced MMPs expression and augmented TIMP-1 gene expression significantly. Atorvastatin 0-12 C-reactive protein Homo sapiens 49-52 19822977-6 2009 Atorvastatin significantly reduced the incidence of postoperative AF and the postoperative peak C-reactive protein (CRP) level vs placebo (14% vs 34%, P=0.009; 126.5 +/-22.3 vs 145.2 +/-31.6 mg/L, P<0.0001). Atorvastatin 0-12 C-reactive protein Homo sapiens 96-114 20682172-8 2010 Atorvastatin (10-20 microM) was able to significantly accelerate the CRP-induced expression of PPAR-gamma and LXR-alpha and attenuate MMP-9 expression. Atorvastatin 0-12 C-reactive protein Homo sapiens 69-72 20682172-9 2010 CONCLUSIONS: For the first time we demonstrate that CRP modulates PPAR-gamma and its effector genes and reinforces the mechanistic link of CRP as a possible mediator in atherosclerosis and also advocate atorvastatin as a therapeutic modality. Atorvastatin 203-215 C-reactive protein Homo sapiens 52-55 20349300-6 2010 C-reactive protein levels were lower in the pravastatin group 72 h after surgery (nonstatin vs. pravastatin, P = 0.0180; atorvastatin vs. pravastatin, P = 0.0383). Atorvastatin 121-133 C-reactive protein Homo sapiens 0-18 20441243-7 2010 RESULTS: In the atorvastatin-treated patients significantly lower plasma levels of thrombin-antithrombin complexes (p < 0.05), plasminogen activator inhibitor-1 activity (PAI-1) [p < 0.05], soluble vascular cell adhesion molecule-1 (p < 0.05), soluble platelet selectin (p < 0.05) and high-sensitivity C-reactive protein (p < 0.05) were measured compared with patients not on atorvastatin therapy. Atorvastatin 16-28 C-reactive protein Homo sapiens 314-332 20074254-0 2010 Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway. Atorvastatin 0-12 C-reactive protein Homo sapiens 23-41 20074254-3 2010 The aims of this study was to examined the effects of CRP on expressions of interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1), and the possible mechanisms of atorvastatin on CRP-induced IL-6 and MCP-1 production in cultured human pulmonary artery smooth muscle cells (PASMCs). Atorvastatin 176-188 C-reactive protein Homo sapiens 192-195 20074254-5 2010 Then, the cells were pre-incubated for 2 h with atorvastatin (0.1-10 micromol/L) in the presence of CRP. Atorvastatin 48-60 C-reactive protein Homo sapiens 100-103 20074254-10 2010 Preincubation with 0.1-10 micromol/L of atorvastatin significantly decreased the secretions of IL-6 and MCP-1 induced by CRP. Atorvastatin 40-52 C-reactive protein Homo sapiens 121-124 20074254-11 2010 Moreover, 10 micromol/L of atorvastatin completely abrogated CRP-induced increase in IL-6 and MCP-1 by attenuating the activation of NF-kappaB. Atorvastatin 27-39 C-reactive protein Homo sapiens 61-64 20074254-12 2010 The present study demonstrated that inhibiting effect of atorvastatin on CRP-induced inflammatory response in cultured PASMCs was associated with NF-kappaB pathway. Atorvastatin 57-69 C-reactive protein Homo sapiens 73-76 19822977-6 2009 Atorvastatin significantly reduced the incidence of postoperative AF and the postoperative peak C-reactive protein (CRP) level vs placebo (14% vs 34%, P=0.009; 126.5 +/-22.3 vs 145.2 +/-31.6 mg/L, P<0.0001). Atorvastatin 0-12 C-reactive protein Homo sapiens 116-119 19067673-9 2009 Reductions in high-sensitivity C-reactive protein were observed in atorvastatin-treated patients with alleles >10/>10 and 10/10. Atorvastatin 67-79 C-reactive protein Homo sapiens 31-49 19708997-6 2009 So far, no specific pharmacologic treatment, including atorvastatin, has been identified that can substantially reduce CRP and accompanying inflammation. Atorvastatin 55-67 C-reactive protein Homo sapiens 119-122 19636689-9 2009 sICAM-1, CRP and vWF levels decreased and FMD increased significantly in the atorvastatin group, but not in the control group. Atorvastatin 77-89 C-reactive protein Homo sapiens 9-12 19636689-11 2009 CONCLUSIONS: Twelve weeks of treatment with atorvastatin significantly decreased serum sICAM-1, CRP and vWF levels, and improved the FMD, LVEF and 6MWT outcomes. Atorvastatin 44-56 C-reactive protein Homo sapiens 96-99 19687343-5 2009 After the 12-week treatment period, the ATOR group experienced a 47% reduction in low-density lipoprotein cholesterol (149+/-6 to 80+/-8 mg/dL) and a 42% reduction in high-sensitivity C-reactive protein (3.6+/-0.8 to 2.1+/-0.5 mg/L; both P<0.05). Atorvastatin 40-44 C-reactive protein Homo sapiens 184-202 19259830-3 2009 We wanted to evaluate and compare the effects of treating with a one-year course of atorvastatin or simvastatin on inflammatory markers such as high sensitive C-reactive protein (hsCRP), fibrinogen, and ferritin in uncontrolled type 2 diabetic patients. Atorvastatin 84-96 C-reactive protein Homo sapiens 159-177 19067673-11 2009 In conclusion, the changes induced by atorvastatin treatment on low-density lipoprotein cholesterol, total cholesterol, triglycerides, high-sensitivity C-reactive protein and free F(2)-isoprostane concentrations were not related to the presence of 3-hydroxy-3-methylglutaryl-coenzyme A reductase polymorphism (TTA)n. Atorvastatin 38-50 C-reactive protein Homo sapiens 152-170 19270348-0 2009 [Effect of atorvastatin on lipopolysaccharide-induced expression of C-reactive protein in human pulmonary epithelial cells]. Atorvastatin 11-23 C-reactive protein Homo sapiens 68-86 19151033-7 2009 RESULTS: Treatment with simvastatin or atorvastatin decreased CRP-induced release of CCL2, CCL3 and CCL4. Atorvastatin 39-51 C-reactive protein Homo sapiens 62-65 19151033-9 2009 Treatments with 1 microM simvastatin or atorvastatin significantly inhibited monocyte migration in response to CRP. Atorvastatin 40-52 C-reactive protein Homo sapiens 111-114 19270348-1 2009 OBJECTIVE: To determine the effect of atorvastatin on lipopolysaccharide-induced expression of C-reactive protein in cultured A549 cells. Atorvastatin 38-50 C-reactive protein Homo sapiens 95-113 19270348-6 2009 Atorvastatin significantly decreased the lipopolysaccharide induced the mRNA expression and the production of C-reactive protein in a dose dependent manner in A549 cells (P<0.05). Atorvastatin 0-12 C-reactive protein Homo sapiens 110-128 19270348-7 2009 CONCLUSION: Atorvastatin downregulates lipopolysaccharide-induced expression of C-reactive protein in cultured A549 cells, which may be its mechanism of anti-inflammation. Atorvastatin 12-24 C-reactive protein Homo sapiens 80-98 18925316-3 2008 OBJECTIVES: To evaluate vasomotor function, lipids and C-reactive protein in mildly hypertensive and hypercholesterolemic elderly patients treated with atorvastatin. Atorvastatin 152-164 C-reactive protein Homo sapiens 55-73 18940877-9 2009 RESULTS: After 12 wk atorvastatin, there was a significant reduction (mean +/- sem) in total cholesterol (4.6 +/- 0.2 vs. 3.4 +/- 0.2 mmol/liter, P < 0.01), low-density lipoprotein cholesterol (2.9 +/- 0.2 vs. 1.8 +/- 0.2 mmol/liter, P < 0.01), triglycerides (1.34 +/- 0.08 vs. 1.08 +/- 0.13 mmol/liter, P <0.01), high-sensitivity C-reactive protein (4.9 +/- 1.4 vs. 3.4 +/- 1.1 mg/liter, P = 0.04), free androgen index (13.4 +/- 0.6 vs. 8.7 +/- 0.4, P < 0.01), testosterone (4.1 +/- 0.2 vs. 2.9 +/- 0.1 nmol/liter, P < 0.01) and insulin resistance as measured by homeostasis model assessment for insulin resistance (HOMA-IR) (3.3 +/- 0.4 vs. 2.7 +/- 0.4). Atorvastatin 21-33 C-reactive protein Homo sapiens 340-358 18806816-6 2008 KEY RESULTS: In 8 of 10 patients, atorvastatin treatment reduced CRP (P=0.008) and sTNFRII (P=0.064). Atorvastatin 34-46 C-reactive protein Homo sapiens 65-68 18806816-9 2008 At the follow-up visit, 8 weeks after the atorvastatin treatment was terminated, CRP levels had returned to those seen before the treatment. Atorvastatin 42-54 C-reactive protein Homo sapiens 81-84 18925316-10 2008 Atorvastatin produced a reduction of 20% of the C-reactive protein and 42% in the LDL-c; however, there were no changes in the flow-mediated dilation. Atorvastatin 0-12 C-reactive protein Homo sapiens 48-66 18925316-11 2008 CONCLUSIONS: Atorvastatin produced a significant change of lipids and C-reactive protein; however, there were no changes in vasomotor function, suggesting the existence of intrinsic age-related vessel alterations. Atorvastatin 13-25 C-reactive protein Homo sapiens 70-88 18573823-0 2008 Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis. Atorvastatin 0-12 C-reactive protein Homo sapiens 40-58 18637893-0 2008 Effect of atorvastatin on hs-CRP in acute coronary syndrome. Atorvastatin 10-22 C-reactive protein Homo sapiens 29-32 18637893-1 2008 AIMS: To evaluate the effect of a lower dose (20 mg) of atorvastatin on hs-CRP concentrations in patients with ACS. Atorvastatin 56-68 C-reactive protein Homo sapiens 75-78 18637893-5 2008 The decrease in hs-CRP was also significantly greater in the subgroups of smoking, hypertension and past history of cardiovascular disease with atorvastatin. Atorvastatin 144-156 C-reactive protein Homo sapiens 19-22 18573823-4 2008 In contrast, when atorvastatin is added to interferon-beta, hs-CRP serum levels decrease to the normal range (P<0.05), indicating an anti-inflammatory action of atorvastatin in MS. Atorvastatin 164-176 C-reactive protein Homo sapiens 63-66 17655947-7 2008 CONCLUSIONS: High dose atorvastatin significantly decreased CRP during the early days of acute coronary syndromes. Atorvastatin 23-35 C-reactive protein Homo sapiens 60-63 18638594-8 2008 Hs-CRP, matrix metalloproteinase-9, and NF-kB significantly decreased in the 80-mg atorvastatin group compared with baseline. Atorvastatin 83-95 C-reactive protein Homo sapiens 3-6 18638594-9 2008 In conclusion, this randomized trial of subjects with MS showed the superiority of atorvastatin 80 mg compared with its 10-mg dose in decreasing oxidized LDL, hs-CRP, matrix metalloproteinase-9, and NF-kB activity. Atorvastatin 83-95 C-reactive protein Homo sapiens 162-165 18573823-2 2008 We evaluated serum levels of high-sensitivity (hs)-CRP in relapsing-remitting MS patients receiving interferon-beta 1b and atorvastatin as add-on therapy. Atorvastatin 123-135 C-reactive protein Homo sapiens 51-54 18573823-4 2008 In contrast, when atorvastatin is added to interferon-beta, hs-CRP serum levels decrease to the normal range (P<0.05), indicating an anti-inflammatory action of atorvastatin in MS. Atorvastatin 18-30 C-reactive protein Homo sapiens 63-66 18000162-3 2008 OBJECTIVE: To evaluate the efficacy of atorvastatin compared with a control group in inducing changes in lipoprotein(a) [Lp(a)], apolipoprotein (Apo) A-1, Apo-B, and fibrinogen levels, as well as the conventional lipoprotein profile, in hemodialysis patients over 36 weeks; secondary objectives were to assess changes in C-reactive protein, albumin, and safety measures. Atorvastatin 39-51 C-reactive protein Homo sapiens 321-339 18389332-0 2008 Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Atorvastatin 37-49 C-reactive protein Homo sapiens 102-120 18608041-0 2008 The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level. Atorvastatin 27-39 C-reactive protein Homo sapiens 99-102 18608041-8 2008 In atorvastatin/high-CRP subgroup, the level of aggregation was about three times lower after eight days than it was on the first day. Atorvastatin 3-15 C-reactive protein Homo sapiens 21-24 18991814-3 2008 Measures of efficacy of therapy with atorvastatin were percent changes of CRP, total (T) cholesterol (CH), and low density lipoprotein (LDL) CH compared with initial values. Atorvastatin 37-49 C-reactive protein Homo sapiens 74-77 19343161-0 2008 Targeting C-reactive protein levels using high-dose atorvastatin before coronary artery bypass graft surgery. Atorvastatin 52-64 C-reactive protein Homo sapiens 10-28 19343161-2 2008 AIM: To determine whether a high loading dose of atorvastatin prescribed before and after coronary artery bypass graft (CABG) surgery will attenuate the inflammatory response reflected in kinetic concentrations of C-reactive protein (CRP). Atorvastatin 49-61 C-reactive protein Homo sapiens 214-232 19343161-2 2008 AIM: To determine whether a high loading dose of atorvastatin prescribed before and after coronary artery bypass graft (CABG) surgery will attenuate the inflammatory response reflected in kinetic concentrations of C-reactive protein (CRP). Atorvastatin 49-61 C-reactive protein Homo sapiens 234-237 19343161-7 2008 CONCLUSIONS: High loading doses of atorvastatin before CABG surgery reduced CRP concentration, expressed as AUC-CRP. Atorvastatin 35-47 C-reactive protein Homo sapiens 76-79 19343161-7 2008 CONCLUSIONS: High loading doses of atorvastatin before CABG surgery reduced CRP concentration, expressed as AUC-CRP. Atorvastatin 35-47 C-reactive protein Homo sapiens 112-115 18991814-6 2008 Most pronounced lowering of CRP took place in a subgroups of IHD patients with initially high CRP level (-20%) and patients with RA (-65%) to whom atorvastatin was prescribed in a dose of 40 mg/day. Atorvastatin 147-159 C-reactive protein Homo sapiens 28-31 18991814-8 2008 CONCLUSION: HMG-CoA-reductase inhibitor atorvastatin more effectively lowers concentration of CRP in blood plasma of patients with PA than with IHD what possibly is explained by higher initial level of this marker of inflammatory processes. Atorvastatin 40-52 C-reactive protein Homo sapiens 94-97 18042053-10 2007 Both statins significantly reduced plasmatic levels of CRP (3.18 +/- 2.43 mg/dL [T0] vs. 1.31 +/- 1.67 mg/dL [T2] with rosuvastatin [P < 0.01], 7.53 +/- 7.46 mg/dL [T0] vs. 2.92 +/- 2.06 mg/dL [T2] with atorvastatin [P < 0.01]). Atorvastatin 206-218 C-reactive protein Homo sapiens 55-58 19227901-0 2008 [Comparison of the effects of carbohydrate metabolism compensation and atorvastatin treatment on lipid metabolism and C-reactive protein in type 2 diabetes mellitus]. Atorvastatin 71-83 C-reactive protein Homo sapiens 118-136 19227901-12 2008 Atorvastatin produces an antiatherogenic effect due to both improvement of the lipid metabolism and CRP level reduction irrespective of the degree of compensation of carbohydrate metabolism in type 2 DM Atorvastatin 0-12 C-reactive protein Homo sapiens 100-103 18042053-11 2007 Relative reduction of CRP levels was -50.57% with rosuvastatin versus -36.28% with atorvastatin (P N.S.). Atorvastatin 83-95 C-reactive protein Homo sapiens 22-25 17130267-10 2006 In addition to the hypolipidemic effect, atorvastatin treatment significantly reduced inflammatory parameters: CRP (median 4.1 to 2.9; P = 0.015), TNF-alpha (6.0 +/- 2.7 to 4.7 +/- 2.4; P = 0.046), and IL-1 beta levels (1.9 +/- 0.7 to 1.2 +/- 0.7; P = 0.001). Atorvastatin 41-53 C-reactive protein Homo sapiens 111-114 17920365-0 2007 Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Atorvastatin 51-63 C-reactive protein Homo sapiens 95-113 17920365-5 2007 In conclusion, CRP was effectively decreased in patients with type 2 diabetes receiving rosuvastatin or atorvastatin, whereas rosuvastatin decreased LDL cholesterol significantly more than atorvastatin. Atorvastatin 104-116 C-reactive protein Homo sapiens 15-18 17344325-12 2007 CONCLUSIONS: In patients with CHD, intensive atorvastatin therapy results in regression of carotid atherosclerotic disease, which is associated with reduction in CRP levels. Atorvastatin 45-57 C-reactive protein Homo sapiens 162-165 17560879-0 2007 Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Atorvastatin 73-85 C-reactive protein Homo sapiens 98-116 17560879-6 2007 Reductions in CRP of similar magnitude were observed with ezetimibe/simvastatin and atorvastatin when averaged across doses and at each milligram-equivalent statin dose comparison. Atorvastatin 84-96 C-reactive protein Homo sapiens 14-17 17537152-6 2007 RESULTS: Atorvastatin therapy significantly improved exercise VO(2) tau and FMD, and reduced CRP levels. Atorvastatin 9-21 C-reactive protein Homo sapiens 93-96 17910519-11 2007 In addition, it has been reported that C-reactive protein levels and the combined incidence of cardiovascular events (death, MI and target segment revascularisation during the 6-month follow-up) were significantly higher in coronaropathic patients undergoing non-surgical revascularisation procedures (stent implantation) not receiving statin therapy compared with those treated with atorvastatin (80mg). Atorvastatin 384-396 C-reactive protein Homo sapiens 39-57 17329034-12 2007 Does the blockade by atorvastain of the AGE signaling pathway, in other words, the suppression of 8-hydroxydeoxyguanosine and CRP levels by atorvastatin treatment, contribute to its cardioprotective properties? Atorvastatin 140-152 C-reactive protein Homo sapiens 126-129 16449511-6 2006 Atorvastatin reduced serum low density lipoprotein cholesterol (-53%, p < 0.001) and C reactive protein (-49%, p < 0.001) concentrations whereas there was no change with placebo (-7% and 17%, p > 0.95 for both). Atorvastatin 0-12 C-reactive protein Homo sapiens 88-106 16480969-0 2006 The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Atorvastatin 14-26 C-reactive protein Homo sapiens 56-59 16740374-0 2006 Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study. Atorvastatin 113-125 C-reactive protein Homo sapiens 36-54 16480969-10 2006 Compared with conventional therapy alone, atorvastatin significantly further reduced serum MPO [P=0.014] and CRP concentrations [P=0.032]. Atorvastatin 42-54 C-reactive protein Homo sapiens 109-112 16480969-12 2006 CONCLUSIONS: Atorvastatin reduced serum MPO and CRP concentrations in patients with ACS. Atorvastatin 13-25 C-reactive protein Homo sapiens 48-51 16741040-1 2006 We investigated the effects of three different daily doses (10 mg, 20 mg, and 40 mg) of atorvastatin, a relatively new and potent statin, on plasma endothelin (ET)-1 and highly sensitive C-reactive protein (CRP) levels in type 2 diabetic subjects. Atorvastatin 88-100 C-reactive protein Homo sapiens 187-205 16741040-8 2006 Similarly, although insignificantly, plasma concentrations of CRP also tended to decrease by 12% and 48%, and paradoxically increased by 18% in diabetic patients treated with 10 mg, 20 mg, and 40 mg atorvastatin, respectively. Atorvastatin 199-211 C-reactive protein Homo sapiens 62-65 16939632-12 2006 The effect of atorvastatin on CRP seems to be dose-dependent. Atorvastatin 14-26 C-reactive protein Homo sapiens 30-33 18473965-6 2006 At present, the evidence from clinical trials is favouring the intensity of the effect on LDL-cholesterol and/or C-reactive protein (CRP) with atorvastatin 80 mg, rather than the use of atorvastatin per se, when greater benefits are observed with the 80 mg dose of atorvastatin compared to other statins. Atorvastatin 143-155 C-reactive protein Homo sapiens 113-131 18473965-6 2006 At present, the evidence from clinical trials is favouring the intensity of the effect on LDL-cholesterol and/or C-reactive protein (CRP) with atorvastatin 80 mg, rather than the use of atorvastatin per se, when greater benefits are observed with the 80 mg dose of atorvastatin compared to other statins. Atorvastatin 143-155 C-reactive protein Homo sapiens 133-136 16442368-7 2006 The median high-sensitivity C-reactive protein levels were significantly reduced statistically from baseline with rosuvastatin 20 mg and atorvastatin 20 mg among all patients and with rosuvastatin 10 and 20 mg and atorvastatin 20 mg in those patients with a baseline C-reactive protein level > 2.0 mg/L. Atorvastatin 137-149 C-reactive protein Homo sapiens 28-46 16324343-0 2005 [Effects of atorvastatin on plasma hypersensitive C-reactive protein and interleukin-6 in patients with acute cerebral infarction]. Atorvastatin 12-24 C-reactive protein Homo sapiens 50-68 16324921-0 2006 Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. Atorvastatin 0-12 C-reactive protein Homo sapiens 67-85 16290998-11 2005 CONCLUSIONS: C-reactive protein lowering with atorvastatin appears to be effective in eliminating PAF during daily life in a significant proportion of patients. Atorvastatin 46-58 C-reactive protein Homo sapiens 13-31 19758923-6 2005 CONCLUSION: After PCI in UA, cyclooxygenase-2 inhibitor rofecoxib added to atorvastatin reduced CRP and IL-6 levels more profoundly than atorvastatin alone at 3- and 6-month after intervention. Atorvastatin 75-87 C-reactive protein Homo sapiens 96-99 16442368-7 2006 The median high-sensitivity C-reactive protein levels were significantly reduced statistically from baseline with rosuvastatin 20 mg and atorvastatin 20 mg among all patients and with rosuvastatin 10 and 20 mg and atorvastatin 20 mg in those patients with a baseline C-reactive protein level > 2.0 mg/L. Atorvastatin 214-226 C-reactive protein Homo sapiens 28-46 17047615-2 2006 Effect of 10 and 20 mg/day atorvastatin on levels of lipids, C-reactive protein, and fibrinogen in patients with ischemic heart disease and hyperlipidemia]. Atorvastatin 27-39 C-reactive protein Homo sapiens 61-79 16369062-1 2005 The aim of the study was to find out whether early use of atorvastatin in patients with acute coronary syndrome is associated with rapid changes of plasma levels of the marker of inflammation -- C-reactive protein. Atorvastatin 58-70 C-reactive protein Homo sapiens 195-213 16369062-9 2005 In patients with acute coronary syndrome early use of atorvastatin was associated with rapid decrease of C-reactive protein level. Atorvastatin 54-66 C-reactive protein Homo sapiens 105-123 16324343-1 2005 OBJECTIVE: To observe the effects of different doses of atorvastatin on the plasma hypersensitive C-reactive protein (hsCRP) and interleukin-6 (IL-6) in patients with acute cerebral infarction. Atorvastatin 56-68 C-reactive protein Homo sapiens 98-116 16125534-4 2005 High-sensitivity C-reactive protein decreased significantly with atorvastatin treatment, from 0.801 (0.243, 1.865) to 0.308 (0.200, 0.804) mg/L (P=.0191). Atorvastatin 65-77 C-reactive protein Homo sapiens 17-35 16126024-4 2005 In PROVE IT-TIMI 22, atorvastatin 80 mg lowered both low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP) at 30 days and 4 months to a greater extent than pravastatin 40 mg. Those who achieved the lowest LDL and the lowest CRP levels at 30 days after ACS had the lowest risk of acute cardiac events. Atorvastatin 21-33 C-reactive protein Homo sapiens 99-117 16126024-4 2005 In PROVE IT-TIMI 22, atorvastatin 80 mg lowered both low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP) at 30 days and 4 months to a greater extent than pravastatin 40 mg. Those who achieved the lowest LDL and the lowest CRP levels at 30 days after ACS had the lowest risk of acute cardiac events. Atorvastatin 21-33 C-reactive protein Homo sapiens 119-122 16126024-4 2005 In PROVE IT-TIMI 22, atorvastatin 80 mg lowered both low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP) at 30 days and 4 months to a greater extent than pravastatin 40 mg. Those who achieved the lowest LDL and the lowest CRP levels at 30 days after ACS had the lowest risk of acute cardiac events. Atorvastatin 21-33 C-reactive protein Homo sapiens 241-244 16126025-8 2005 CRP decreased 5.2% with pravastatin and 36.4% with atorvastatin (p <0.0001). Atorvastatin 51-63 C-reactive protein Homo sapiens 0-3 15864233-2 2005 We assessed the hypothesis that atorvastatin might have anti-inflammatory effects in acute coronary syndromes (ACS) as shown by CRP reduction. Atorvastatin 32-44 C-reactive protein Homo sapiens 128-131 16092057-14 2005 C-reactive protein was significantly reduced in all treatment groups, with the atorvastatin and combination groups having the greatest reduction (65% and 68%, respectively, P < .01 vs the fenofibrate group, 44%). Atorvastatin 79-91 C-reactive protein Homo sapiens 0-18 16092057-18 2005 Atorvastatin and combination treatment were more effective than fenofibrate alone in reducing CRP levels. Atorvastatin 0-12 C-reactive protein Homo sapiens 94-97 16053827-7 2005 After the atorvastatin dose was increased, significant reductions in CRP, F1+2, and PAI-1 levels were observed (P<.05). Atorvastatin 10-22 C-reactive protein Homo sapiens 69-72 15842965-0 2005 Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Atorvastatin 11-23 C-reactive protein Homo sapiens 73-91 16086647-3 2005 At 18 months follow-up, the CRP levels were reduced from a baseline level of 2.8 mg/l to 1.8 mg/l by atorvastatin, whereas pravastatin had little effect, and there was a good correlation between both the ultrasonographic progression of disease and the reduction in CRP levels. Atorvastatin 101-113 C-reactive protein Homo sapiens 28-31 16086647-3 2005 At 18 months follow-up, the CRP levels were reduced from a baseline level of 2.8 mg/l to 1.8 mg/l by atorvastatin, whereas pravastatin had little effect, and there was a good correlation between both the ultrasonographic progression of disease and the reduction in CRP levels. Atorvastatin 101-113 C-reactive protein Homo sapiens 265-268 15893181-3 2005 METHODS: We addressed the relative efficacy of pravastatin 40 mg and atorvastatin 80 mg daily to reduce LDL-C and CRP among 3,745 acute coronary syndrome patients. Atorvastatin 69-81 C-reactive protein Homo sapiens 114-117 15864233-8 2005 C-reactive protein levels were lower in the atorvastatin group versus control group at discharge (1.68 +/- 1.65 vs 4.12 +/- 4.18 mg/dL) and at 30 days (0.50 +/- 0.71 vs 2.91 +/- 2.68 mg/dL, both P < .0001). Atorvastatin 44-56 C-reactive protein Homo sapiens 0-18 15864233-9 2005 C-reactive protein levels significantly decreased from baseline to discharge and 1 month later in placebo and atorvastatin groups (both P < .0001); however, the reduction was greater in the atorvastatin group (62% vs 11% at discharge [P < .0001]; 84% vs 30% at 1 month [P < .0001]). Atorvastatin 110-122 C-reactive protein Homo sapiens 0-18 15864233-9 2005 C-reactive protein levels significantly decreased from baseline to discharge and 1 month later in placebo and atorvastatin groups (both P < .0001); however, the reduction was greater in the atorvastatin group (62% vs 11% at discharge [P < .0001]; 84% vs 30% at 1 month [P < .0001]). Atorvastatin 193-205 C-reactive protein Homo sapiens 0-18 15864233-12 2005 CONCLUSIONS: C-reactive protein levels in ACS were rapidly reduced with atorvastatin. Atorvastatin 72-84 C-reactive protein Homo sapiens 13-31 15843280-9 2005 Atorvastatin therapy was associated with no change in mean LDL particle size (p=0.23) and with a 90% decrease in mean CRP level (p=0.52). Atorvastatin 0-12 C-reactive protein Homo sapiens 118-121 15843280-12 2005 CONCLUSION: Treatment with atorvastatin did not affect LDL particle size but was associated with a sizable, yet nonsignificant, reduction in CRP concentrations. Atorvastatin 27-39 C-reactive protein Homo sapiens 141-144 15488879-9 2004 The percentage of patients with CRP levels >3 mg/dL in the atorvastatin group fell from 25.0 to 6.7% (P <0.0001) while in the diet group the reduction was not significant. Atorvastatin 62-74 C-reactive protein Homo sapiens 32-35 15635109-3 2005 METHODS: We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes. Atorvastatin 118-130 C-reactive protein Homo sapiens 68-71 15635109-7 2005 Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Atorvastatin 9-21 C-reactive protein Homo sapiens 102-105 15488879-10 2004 CONCLUSION: In hypercholesterolemic patients, atorvastatin, compared to diet alone resulted in significant reductions in levels of proinflammatory cytokines (TNF, IL-1 and IL-6) as well as in sICAM-1 and CRP. Atorvastatin 46-58 C-reactive protein Homo sapiens 192-207 15312437-10 2004 Atorvastatin inhibited the function of DC and lowered blood level of CRP and CD86, the levels of which were significantly positively correlated. Atorvastatin 0-12 C-reactive protein Homo sapiens 69-72 15535926-0 2004 [Atorvastatin lowers C-reactive protein in dislipemic patients with type 2 diabetes mellitus]. Atorvastatin 1-13 C-reactive protein Homo sapiens 21-39 15535926-4 2004 Thus, we tested the effects of atorvastatin on levels of CRP on patients with type 2 diabetes. Atorvastatin 31-43 C-reactive protein Homo sapiens 57-60 15535926-5 2004 PATIENTS AND METHOD: We evaluated CRP in baseline and 6 months after onset of 20 mg daily atorvastatin therapy of 30 patients with type 2 diabetes with hyperlipidemia. Atorvastatin 90-102 C-reactive protein Homo sapiens 34-37 15535926-7 2004 RESULTS: CRP-levels were significantly decreased after treatment with atorvastatin compared with baseline (median change: -4,99 mg/l; p < 0.001). Atorvastatin 70-82 C-reactive protein Homo sapiens 9-12 15535926-11 2004 CONCLUSIONS: These results confirm findings from previous studies that atorvastatin reduce CRP levels in a largely LDL cholesterol independent manner. Atorvastatin 71-83 C-reactive protein Homo sapiens 91-94 15451915-10 2004 In the interventional study, atorvastatin decreased lipid and CRP levels, but adiponectin and resistin were not specifically altered. Atorvastatin 29-41 C-reactive protein Homo sapiens 62-65 15540478-8 2004 The MIRACL study showed that atorvastatin reduced CRP levels by 83% (p < 0.001). Atorvastatin 29-41 C-reactive protein Homo sapiens 50-53 15540478-9 2004 Researchers in the CURVES study found a significant reduction in CRP levels with pravastatin, simvastatin, and atorvastatin compared with baseline (p < 0.025). Atorvastatin 111-123 C-reactive protein Homo sapiens 65-68 15540478-10 2004 Results of the REVERSAL study linked atorvastatin with a 36.4% decrease in CRP levels, while pravastatin was associated with a 5.2% decrease (p < 0.0001). Atorvastatin 37-49 C-reactive protein Homo sapiens 75-78 15334369-12 2004 High sensitive C-reactive protein (HS-CRP) was halved by atorvastatin decreasing from 0.08 +/- 0.05 to 0.04 +/- 0.03 mg/dL. Atorvastatin 57-69 C-reactive protein Homo sapiens 15-33 14996776-10 2004 C-reactive protein decreased 5.2% with pravastatin and 36.4% with atorvastatin (P<.001). Atorvastatin 66-78 C-reactive protein Homo sapiens 0-18 14981605-0 2004 Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Atorvastatin 5-17 C-reactive protein Homo sapiens 34-52 14981605-3 2004 METHODS: We designed a 6-month, prospective, randomized, controlled study to assess the safety and efficacy of atorvastatin in reducing serum CRP levels in long-term HD patients. Atorvastatin 111-123 C-reactive protein Homo sapiens 142-145 14981605-14 2004 CONCLUSION: Administration of atorvastatin is safe in patients on long-term HD therapy and, in addition to its beneficial effects on lipid levels, induces a significant decrease in serum CRP levels, with a consequential increase in serum albumin levels. Atorvastatin 30-42 C-reactive protein Homo sapiens 187-190 12953165-0 2003 Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Atorvastatin 116-128 C-reactive protein Homo sapiens 67-85 15340345-8 2004 Platelet aggregation decreased only in atorvastatin 40 mg/day group (p<0.05) and CRP decreased in combined atorvastatin group (p<0.05). Atorvastatin 110-122 C-reactive protein Homo sapiens 84-87 14636905-8 2003 High-sensitivity C-reactive protein median values were reduced by 33% to 34% in both the 80-mg rosuvastatin- and atorvastatin-treated groups. Atorvastatin 113-125 C-reactive protein Homo sapiens 17-35 12975259-9 2003 By 16 weeks, CRP was 34% lower with atorvastatin than with placebo. Atorvastatin 36-48 C-reactive protein Homo sapiens 13-16 12925055-7 2003 RESULTS: CRP decreased significantly in the atorvastatin-treated group compared with the placebo group (percent change respect initial values; -42.3 %[-21.5 to - 63.1] and -9.6%[15.0 to -34.0], respectively, p<0.01). Atorvastatin 44-56 C-reactive protein Homo sapiens 9-12 12953165-2 2003 The aim of this study was to investigate the effects of three months of treatment with low dose atorvastatin on serum levels of adhesion molecules, interleukin-6 (IL-6) and highly sensitive C-reactive protein (hs-CRP) in patients with non-familial hypercholesterolemia. Atorvastatin 96-108 C-reactive protein Homo sapiens 190-208 12595863-0 2003 Effect of atorvastatin and pravastatin on serum C-reactive protein. Atorvastatin 10-22 C-reactive protein Homo sapiens 48-66 12768071-0 2003 Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. Atorvastatin 0-12 C-reactive protein Homo sapiens 83-101 12595863-4 2003 RESULTS: Mean C-reactive protein (CRP) levels were significantly reduced in both groups, with a 36% reduction in the atorvastatin group (0.39 +/- 0.36 to 0.25 +/- 0.27, P =.001) and a 22% reduction observed in the pravastatin group (0.40 +/- 0.33 to 0.31 +/- 0.32, P =.003). Atorvastatin 117-129 C-reactive protein Homo sapiens 14-32 12595863-4 2003 RESULTS: Mean C-reactive protein (CRP) levels were significantly reduced in both groups, with a 36% reduction in the atorvastatin group (0.39 +/- 0.36 to 0.25 +/- 0.27, P =.001) and a 22% reduction observed in the pravastatin group (0.40 +/- 0.33 to 0.31 +/- 0.32, P =.003). Atorvastatin 117-129 C-reactive protein Homo sapiens 34-37 12595863-5 2003 A reduced or unchanged CRP level was seen in 67.2% of pravastatin-treated patients (45/67) and 73% of atorvastatin- treated patients (46/63) (P =.47). Atorvastatin 102-114 C-reactive protein Homo sapiens 23-26 12595863-7 2003 However, whereas the reduction of CRP with pravastatin was unrelated to the degree of low-density lipoprotein reduction (r = -.05, P =.69), atorvastatin-induced CRP reductions correlated directly to the change in low-density lipoprotein-C (r =.33, P =.009). Atorvastatin 140-152 C-reactive protein Homo sapiens 161-164 12595863-8 2003 CONCLUSIONS: High-dose atorvastatin and pravastatin both reduce CRP levels. Atorvastatin 23-35 C-reactive protein Homo sapiens 64-67 12564455-1 2003 Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atorvastatin 10-22 C-reactive protein Homo sapiens 59-77 12803732-0 2003 Atorvastatin affects C-reactive protein levels in patients with coronary artery disease. Atorvastatin 0-12 C-reactive protein Homo sapiens 21-39 12803732-2 2003 The aim of this study was to evaluate anti-inflammatory effects of atorvastatin in patients with CAD by measuring serum CRP levels. Atorvastatin 67-79 C-reactive protein Homo sapiens 120-123 12803732-10 2003 CONCLUSIONS: In patients with CAD, atorvastatin exerted an anti-inflammatory effect represented by decreasing CRP levels. Atorvastatin 35-47 C-reactive protein Homo sapiens 110-113 12356402-0 2002 Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events. Atorvastatin 10-22 C-reactive protein Homo sapiens 94-112 12482559-3 2003 RESULTS: Median CRP levels increased with 6.6% in the placebo group and were reduced by 15 and 47%, respectively, with atorvastatin 10 and 80 mg (P<0.001; significantly different from 10 mg atorvastatin and from placebo (P<0.001). Atorvastatin 119-131 C-reactive protein Homo sapiens 16-19 12482559-6 2003 CONCLUSIONS: In DM2 patients high dose atorvastatin induced a strong reduction in CRP levels. Atorvastatin 39-51 C-reactive protein Homo sapiens 82-85 12891281-8 2003 However combination of 2 atorvastatin groups (n=59) revealed decrease of CRP by 18% from baseline on day 14 (from 6.94+/-0.97 to 4.76+/-0.76 mg/l, p=0.028). Atorvastatin 25-37 C-reactive protein Homo sapiens 73-76 12891281-10 2003 CONCLUSION: In otherwise conventionally treated patients with non-ST elevation acute coronary syndrome early use of atorvastatin was associated with rapid (in 14 days) decrease of CRP level. Atorvastatin 116-128 C-reactive protein Homo sapiens 180-183 12945719-5 2003 On the other hand, five patients with rheumatoid arthritis (RA) who received atorvastatin for eight days (20mg/day) showed reduction in C-reactive protein levels and a clinical improvement that was classified as an ACR20 response. Atorvastatin 77-89 C-reactive protein Homo sapiens 136-154 11996943-0 2002 Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atorvastatin 10-22 C-reactive protein Homo sapiens 59-77 11996943-3 2002 The present study evaluated the effects of atorvastatin (10-40 mg) and bezafibrate (400 mg) on CRP concentrations after 6 and 12 months of treatment in 103 patients with combined (mixed) hyperlipidemia. Atorvastatin 43-55 C-reactive protein Homo sapiens 95-98 11996943-5 2002 After 6 months and 1 year, atorvastatin treatment was associated with significant (P<0.001) decreases from baseline of CRP concentrations by 29 and 43%, respectively, while bezafibrate-treated patients showed non-significant reductions of 2.3 and 14.6%, respectively (P=0.056 and 0.005 for the respective differences between the two treatment arms at 6 months and 1 year). Atorvastatin 27-39 C-reactive protein Homo sapiens 122-125 11996943-7 2002 Covariance analysis showed that CRP decreases in the atorvastatin group were unrelated to total cholesterol and LDL cholesterol reductions; however, they were directly related to triglyceride changes (r=0.28, P=0.047) and inversely related to HDL cholesterol changes (r=-0.28, P=0.045). Atorvastatin 53-65 C-reactive protein Homo sapiens 32-35 11996943-8 2002 A model including baseline CRP values and treatment effect showed that atorvastatin use was a significant predictor of change in CRP levels over time (beta=0.82, P=0.023). Atorvastatin 71-83 C-reactive protein Homo sapiens 27-30 11996943-8 2002 A model including baseline CRP values and treatment effect showed that atorvastatin use was a significant predictor of change in CRP levels over time (beta=0.82, P=0.023). Atorvastatin 71-83 C-reactive protein Homo sapiens 129-132 12008177-0 2002 Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Atorvastatin 54-66 C-reactive protein Homo sapiens 113-131 12009719-6 2002 The decrease in CRP lowering was thus fully established by 1 month and this response was independent of lipid and lipoprotein changes as well as atorvastatin doses. Atorvastatin 145-157 C-reactive protein Homo sapiens 16-19 12009719-7 2002 CONCLUSION: Atorvastatin significantly decreases CRP concentrations after 4 weeks of therapy. Atorvastatin 12-24 C-reactive protein Homo sapiens 49-52 12009719-0 2002 Short-term effects of atorvastatin on C-reactive protein. Atorvastatin 22-34 C-reactive protein Homo sapiens 38-56 34872404-6 2021 RESULTS: Compared to placebo, 7-day atorvastatin increased the recognition (p = 0.006), discriminability (p = 0.03) and misclassifications (p = 0.04) of fearful facial expression, independently from subjective states of mood and anxiety, and C-reactive protein levels. Atorvastatin 36-48 C-reactive protein Homo sapiens 242-260 12009719-1 2002 AIM: To study the short-term effect of atorvastatin on C-reactive protein (CRP) in patients with or at risk for coronary heart disease. Atorvastatin 39-51 C-reactive protein Homo sapiens 55-73 12009719-1 2002 AIM: To study the short-term effect of atorvastatin on C-reactive protein (CRP) in patients with or at risk for coronary heart disease. Atorvastatin 39-51 C-reactive protein Homo sapiens 75-78 11952885-8 2002 CRP and SAA was significantly reduced by atorvastatin, whilst no reduction was seen for simvastatin. Atorvastatin 41-53 C-reactive protein Homo sapiens 0-3 11952885-12 2002 CONCLUSION: Atorvastatin reduced the liver-derived acute-phase reactants, CRP and SAA, whilst the effect of simvastatin was small or absent. Atorvastatin 12-24 C-reactive protein Homo sapiens 74-77 11836286-0 2002 Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. Atorvastatin 0-12 C-reactive protein Homo sapiens 20-38 11836286-7 2002 At 6 months, plasma CRP decreased in the atorvastatin group compared with baseline (P < 0.05). Atorvastatin 41-53 C-reactive protein Homo sapiens 20-23 15526541-7 2002 In coronary heart disease patients, Atorvastatin reduced homocystein concentrations with 19.41% (baseline 17.7 +/- 11.16 microM/l) (p < 0.01), and CRP with 21.9% (baseline 4.8 +/- 4.19 mg/l) p < 0.01 and TBARS with 52% (baseline 0.87 +/- 0.89 nM/ml) p < 0.001, but did not influence sICAM and Ab oxLDL. Atorvastatin 36-48 C-reactive protein Homo sapiens 150-153 11306519-5 2001 hs-CRP levels were significantly decreased after treatment with all 3 statins compared with baseline (median values: baseline, 2.6 mg/L; atorvastatin, 1.7 mg/L; simvastatin, 1.7 mg/L; and pravastatin, 1.9 mg/L; P<0.025). Atorvastatin 137-149 C-reactive protein Homo sapiens 3-6 11306519-9 2001 CONCLUSIONS: Pravastatin, simvastatin, and atorvastatin significantly decreased levels of hs-CRP. Atorvastatin 43-55 C-reactive protein Homo sapiens 93-96 33224343-5 2020 Among statins, rosuvastatin had the strongest interaction with CRP (pKi = 16.14), followed by fluvastatin (pKi = 15.58), pitavastatin (pKi = 15.26), atorvastatin (pKi = 14.68), pravastatin (pKi = 13.95), simvastatin (pKi = 7.98) and lovastatin (pKi = 7.10). Atorvastatin 149-161 C-reactive protein Homo sapiens 63-66 34302321-0 2021 Effects of Atorvastatin on T-Cell Activation and Apoptosis in Systemic Lupus Erythematosus and Novel Simulated Interactions With C-Reactive Protein and Interleukin 6. Atorvastatin 11-23 C-reactive protein Homo sapiens 129-147 34302321-12 2021 Atorvastatin interacted strongly with C-reactive protein (CRP) and also significantly with IL-6. Atorvastatin 0-12 C-reactive protein Homo sapiens 38-56 34302321-12 2021 Atorvastatin interacted strongly with C-reactive protein (CRP) and also significantly with IL-6. Atorvastatin 0-12 C-reactive protein Homo sapiens 58-61 34302321-17 2021 We determine for the first time simulated interaction between atorvastatin, CRP, and IL-6, implying a novel role of atorvastatin. Atorvastatin 116-128 C-reactive protein Homo sapiens 76-79 34779013-11 2022 Significant reductions in C-reactive protein (CRP) were seen for atorvastatin versus placebo (MD: -1.51 mmol/L; 95% CI: -3.26 to 0.24, I2 = 75%, very low-grade evidence). Atorvastatin 65-77 C-reactive protein Homo sapiens 26-44 34779013-11 2022 Significant reductions in C-reactive protein (CRP) were seen for atorvastatin versus placebo (MD: -1.51 mmol/L; 95% CI: -3.26 to 0.24, I2 = 75%, very low-grade evidence). Atorvastatin 65-77 C-reactive protein Homo sapiens 46-49 34779013-13 2022 There was also a significant reduction of CRP with atorvastatin. Atorvastatin 51-63 C-reactive protein Homo sapiens 42-45 34541293-9 2021 CRP level was significantly decreased in the lopinavir/ritonavir + atorvastatin group (P < 0.0001, Cohen"s d = 0.865) so that there was a significant difference in CRP level on the 6th day between the two groups (P = 0.01). Atorvastatin 67-79 C-reactive protein Homo sapiens 0-3 34541293-9 2021 CRP level was significantly decreased in the lopinavir/ritonavir + atorvastatin group (P < 0.0001, Cohen"s d = 0.865) so that there was a significant difference in CRP level on the 6th day between the two groups (P = 0.01). Atorvastatin 67-79 C-reactive protein Homo sapiens 164-167 35198792-11 2022 The activity of atorvastatin will include assessment of C-reactive protein or high sensitivity C-reactive protein and white blood cell levels. Atorvastatin 16-28 C-reactive protein Homo sapiens 56-74 35198792-11 2022 The activity of atorvastatin will include assessment of C-reactive protein or high sensitivity C-reactive protein and white blood cell levels. Atorvastatin 16-28 C-reactive protein Homo sapiens 95-113 33952812-9 2022 RESULTS: Atorvastatin, but not the diet-only treatment, significantly reduced LDL-cholesterol (LDL-C, -43%), serum CRP (-37%) and S100A12 levels (-28%) and improved FMD (+38%). Atorvastatin 9-21 C-reactive protein Homo sapiens 115-118 33952812-12 2022 CONCLUSIONS: Atorvastatin treatment reduced S100A12/CRP levels, and the changes in these circulating markers mirrored the improvement in arterial inflammation. Atorvastatin 13-25 C-reactive protein Homo sapiens 52-55 33224343-6 2020 According to the above-mentioned results, rosuvastatin, fluvastatin, pitavastatin and atorvastatin were found to have stronger binding to CRP compared with the standard ligand phosphocholine (pKi = 14.55). Atorvastatin 86-98 C-reactive protein Homo sapiens 138-141 33080990-8 2020 Accordingly, the inhibitory effect of CRP on the ATP-induced interleukin-1beta release was blunted in monocytes from coronary heart disease patients treated with atorvastatin compared to monocytes obtained before medication. Atorvastatin 162-174 C-reactive protein Homo sapiens 38-41 32598808-0 2019 [Preprocedural high - sensitivity C-reactive protein (hsCRP) decrease during intensive atorvastatin therapy: the presumable impact on atherosclerosis progression after coronary stenting]. Atorvastatin 87-99 C-reactive protein Homo sapiens 34-52 31228727-8 2019 Combining 12 effect sizes from 11 studies, a significant reduction was found in serum CRP concentrations following administration of Atorvastatin (WMD: -0.57; 95% CI: -0.78, -0.35). Atorvastatin 133-145 C-reactive protein Homo sapiens 86-89 33380704-6 2020 Results: : Both candesartan and atorvastatin treated groups showed significant decrease in serum levels IL-1beta and TNF-alpha, acute-phase reactants (CRP and ESR), number of swollen joint and patient global assessment. Atorvastatin 32-44 C-reactive protein Homo sapiens 151-154 30674312-6 2019 Network meta-analysis showed that Fluvastatin (97.7%), Atorvastatin (68.0%) and Rosuvastatin (49.3%) had higher cumulative probability than other statins in reducing CRP in COPD patients. Atorvastatin 55-67 C-reactive protein Homo sapiens 166-169 30983166-12 2019 C-reactive protein level was also significantly lower in the atorvastatin group than the placebo group (median 2.59 mg/liter [IQR 0.94, 6.08] versus 3.60 mg/liter [IQR 1.47, 7.49]; P < 0.0001). Atorvastatin 61-73 C-reactive protein Homo sapiens 0-18 30674312-9 2019 In addition, Fluvastatin and Atorvastatin are more effective in reducing CRP and PH in COPD patients. Atorvastatin 29-41 C-reactive protein Homo sapiens 73-76 30328360-8 2019 Total cholesterol, low-density lipoprotein cholesterol, triglycerides and C-reactive protein were reduced only in the atorvastatin-treated participants. Atorvastatin 118-130 C-reactive protein Homo sapiens 74-92 29343081-9 2018 Use of high and moderate atorvastatin therapy significantly reduced low-density lipoprotein and total cholesterol levels, as well as plasma levels of CRP, MPO, nitrite, and TBARS, and increased plasma SOD activity in patients with moderate to very high risk of ASCVD, independent of lipid-lowering effects. Atorvastatin 25-37 C-reactive protein Homo sapiens 150-153 29793637-0 2018 Impact of C-Reactive Protein and Coronary Artery Calcium on Benefit Observed With Atorvastatin. Atorvastatin 82-94 C-reactive protein Homo sapiens 10-28 28685957-9 2018 Atorvastatin significantly reduced homocysteine and C-reactive protein, and delayed and reversed the progress of carotid atherosclerosis in very elderly patients with type 2 diabetes. Atorvastatin 0-12 C-reactive protein Homo sapiens 52-70 29353098-11 2018 Nine studies reported a change in C-Reactive Protein (CRP) after atorvastatin treatment, and the pooled analysis showed that atorvastatin decreased CRP in RA patients by x +- SD95% [SMD = -3.033, 95%CI = (-4.460, -1.606), p = .000]. Atorvastatin 125-137 C-reactive protein Homo sapiens 34-52 29353098-11 2018 Nine studies reported a change in C-Reactive Protein (CRP) after atorvastatin treatment, and the pooled analysis showed that atorvastatin decreased CRP in RA patients by x +- SD95% [SMD = -3.033, 95%CI = (-4.460, -1.606), p = .000]. Atorvastatin 125-137 C-reactive protein Homo sapiens 54-57 29353098-11 2018 Nine studies reported a change in C-Reactive Protein (CRP) after atorvastatin treatment, and the pooled analysis showed that atorvastatin decreased CRP in RA patients by x +- SD95% [SMD = -3.033, 95%CI = (-4.460, -1.606), p = .000]. Atorvastatin 125-137 C-reactive protein Homo sapiens 148-151